Chugai Pharmaceutical Co., Ltd.
Phone: 81-(0)3-3281-6611
Fax: 81-(0)3-3281-6607
E-mail: Via Site
Web: https://www.chugai-pharm.co.jp
| Native name | 中外製薬株式会社 |
|---|---|
| Romanized name | Chūgai Seiyaku kabushiki gaisha |
| Type | Public KK |
| Traded as |
|
| Industry | Pharmaceutical Industry, Business import, production and development of drugs for medical sales |
| Founded | March 8, 1943 |
| Headquarters | Nihonbashi Mitsui Tower, Nihonbashi Muromachi 2-1-1, Chūō, Tokyo On the registration Headquarter: Tokyo Kita (Tokyo) |
| Key people | Osamu Nagayama - Chairman and Tatsuro Kosaka - CEO |
| Revenue | 72.9 billion capital of 47 million yen. Standalone sales of 329.2 billion yen and 344.8 billion yen consolidated (December 2007) |
| Parent | Hoffmann-La Roche (61.62%) |
| Website | www.chugai-pharm.co.jp (in Japanese) |
Chugai's mission is to create innovative drugs for the benefit of patients. As a research-based pharmaceutical company, Chugai specializes in the research, development, production and marketing of prescription pharmaceuticals. We have established the following business processes to create innovative medicines.
For detailed contact information visit location pages below.
Chugai Pharmaceutical Co., Ltd.'s locations around the world
Asia
Clinical Trials sponsored by Chugai Pharmaceutical Co., Ltd.
-
Chugai Pharmaceutical招待による登録抗リン脂質症候群（APS） | 免疫性血小板減少症 (ITP) | 皮膚筋炎（DM） | 水疱性類天疱瘡（BP） | ベーチェット症候群 (BS) | 免疫介在性壊死性筋症 (IMNM)ハンガリー, オーストラリア, 日本, ドイツ, 台湾, オーストリア, ブルガリア, クロアチア, フランス, イタリア, オランダ, ノルウェー, ポルトガル, ルーマニア, カナダ, スペイン, チェコ, ポーランド, トルコ（Türkiye）